KR100891398B1 - 신규한 스트렙토코커스 항원 - Google Patents

신규한 스트렙토코커스 항원 Download PDF

Info

Publication number
KR100891398B1
KR100891398B1 KR1020067025282A KR20067025282A KR100891398B1 KR 100891398 B1 KR100891398 B1 KR 100891398B1 KR 1020067025282 A KR1020067025282 A KR 1020067025282A KR 20067025282 A KR20067025282 A KR 20067025282A KR 100891398 B1 KR100891398 B1 KR 100891398B1
Authority
KR
South Korea
Prior art keywords
glu
lys
ser
ala
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067025282A
Other languages
English (en)
Korean (ko)
Other versions
KR20060134227A (ko
Inventor
조세 하멜
버나드 알. 브로데어
클레멘트 라이우스
이사벨 피뉴
데니스 마틴
나탈리 카를랜드
Original Assignee
아이디 바이오메디칼 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100891398(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아이디 바이오메디칼 코포레이션 filed Critical 아이디 바이오메디칼 코포레이션
Publication of KR20060134227A publication Critical patent/KR20060134227A/ko
Application granted granted Critical
Publication of KR100891398B1 publication Critical patent/KR100891398B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020067025282A 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원 Expired - Fee Related KR100891398B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
US60/113,800 1998-12-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020017007963A Division KR100802198B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087008264A Division KR101170203B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원

Publications (2)

Publication Number Publication Date
KR20060134227A KR20060134227A (ko) 2006-12-27
KR100891398B1 true KR100891398B1 (ko) 2009-04-02

Family

ID=22351610

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020067025282A Expired - Fee Related KR100891398B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원
KR1020017007963A Expired - Fee Related KR100802198B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원
KR1020107009285A Expired - Fee Related KR101078919B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원
KR1020087008264A Expired - Fee Related KR101170203B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020017007963A Expired - Fee Related KR100802198B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원
KR1020107009285A Expired - Fee Related KR101078919B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원
KR1020087008264A Expired - Fee Related KR101170203B1 (ko) 1998-12-23 1999-12-20 신규한 스트렙토코커스 항원

Country Status (29)

Country Link
EP (2) EP1141306B1 (https=)
JP (2) JP4761623B2 (https=)
KR (4) KR100891398B1 (https=)
CN (3) CN100398653C (https=)
AP (1) AP2001002199A0 (https=)
AR (1) AR029322A1 (https=)
AT (1) ATE394489T1 (https=)
AU (1) AU1764900A (https=)
BR (1) BR9916477A (https=)
CA (1) CA2356836C (https=)
CL (1) CL2009002037A1 (https=)
CY (3) CY1108223T1 (https=)
CZ (2) CZ302790B6 (https=)
DE (1) DE69938670D1 (https=)
DK (3) DK2261358T3 (https=)
EA (1) EA007409B1 (https=)
ES (3) ES2400280T3 (https=)
HU (1) HU229664B1 (https=)
IL (3) IL143905A0 (https=)
MX (1) MXPA01006427A (https=)
NO (1) NO330800B1 (https=)
NZ (1) NZ512574A (https=)
OA (1) OA11736A (https=)
PL (3) PL206576B1 (https=)
PT (3) PT1141306E (https=)
TR (2) TR200200633T2 (https=)
UY (1) UY25877A1 (https=)
WO (1) WO2000039299A2 (https=)
ZA (1) ZA200105114B (https=)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540281T3 (es) 1998-02-20 2015-07-09 Id Biomedical Corporation Of Quebec Antígenos de estreptococos del grupo B
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
ES2322306T3 (es) * 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
DE60136356D1 (de) * 2000-06-12 2008-12-11 Univ Saskatchewan Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
AU2001270381B2 (en) 2000-06-20 2007-05-24 Id Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
AU2002242549A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
WO2003004650A2 (en) * 2001-07-06 2003-01-16 Shire Biochem Inc. Group b streptococcus antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP1456231A2 (en) * 2001-12-20 2004-09-15 Shire Biochem Inc. Streptococcus antigens
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
BRPI0814127A2 (pt) * 2007-07-23 2015-02-03 Sanofi Pasteur Ltd Polipeptídeos imunegênicos e anticorpos monoclonais
SI2271360T1 (sl) 2008-04-16 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo
EP2349209A2 (en) 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
AU2010243285B2 (en) 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
PE20161551A1 (es) 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR20140009281A (ko) 2010-12-03 2014-01-22 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 스트렙토코커스 뉴모니애에 대한 면역화를 위한 조성물
US9393294B2 (en) 2011-01-20 2016-07-19 Genocea Biosciences, Inc. Vaccines and compositions against Streptococcus pneumoniae
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
WO2012156391A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
ES2642184T3 (es) * 2012-01-05 2017-11-15 Deutsches Krebsforschungszentrum Péptidos para su uso en el tratamiento y diagnóstico de cánceres positivos a IDH1 R132H
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016016580B1 (pt) 2014-01-21 2024-01-09 Pfizer Inc Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
EP3104886B1 (en) 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
BR112022001654A2 (pt) 2019-07-31 2022-07-12 Sanofi Pasteur Inc Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
NZ790372A (en) 2020-02-23 2026-01-30 Pfizer Escherichia coli compositions and methods thereof
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CN119317445A (zh) 2022-05-11 2025-01-14 辉瑞公司 用于生产含有防腐剂的疫苗制剂的方法
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP4694921A1 (en) 2023-04-14 2026-02-18 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4701656A1 (en) 2023-04-24 2026-03-04 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DK0656014T3 (da) * 1993-03-19 2003-08-11 Gunnar Lindahl Protein Rib, et celleoverfladeprotein der overfører immunitet mod mange gruppe B Streptococcus stammer, fremgangsmåde til oprensning af proteinet, reagenskit og farmaceutisk komposition
CZ394297A3 (cs) * 1995-06-07 1998-04-15 Biochem Vaccines Inc. Streptokokové proteiny teplotního šoku ze skupiny HSP70
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
JP4469026B2 (ja) * 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
EP1017828A1 (en) * 1997-09-24 2000-07-12 Regents Of The University Of Minnesota HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE)
JP2002516251A (ja) * 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
DE69935986D1 (de) * 1998-07-27 2007-06-14 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
JP2002526082A (ja) * 1998-09-24 2002-08-20 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ストレプトコッカス・ニューモニア由来のヒト補体ｃ３分解ポリペプチド
ES2322306T3 (es) * 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos

Also Published As

Publication number Publication date
KR20010104693A (ko) 2001-11-26
EP2261358A2 (en) 2010-12-15
EA200100565A1 (ru) 2002-04-25
WO2000039299A2 (en) 2000-07-06
NO20013045D0 (no) 2001-06-19
ES2400280T3 (es) 2013-04-08
JP4761623B2 (ja) 2011-08-31
CZ302790B6 (cs) 2011-11-09
CN1654657A (zh) 2005-08-17
CZ303675B6 (cs) 2013-02-27
ES2306528T3 (es) 2008-11-01
HU229664B1 (en) 2014-04-28
CY1115340T1 (el) 2017-01-04
JP5039802B2 (ja) 2012-10-03
HK1118575A1 (en) 2009-02-13
DK1950302T3 (da) 2013-01-14
DK1141306T3 (da) 2008-08-18
KR101078919B1 (ko) 2011-11-01
EP1141306B1 (en) 2008-05-07
KR20060134227A (ko) 2006-12-27
NZ512574A (en) 2004-03-26
IL143905A0 (en) 2002-04-21
PT1950302E (pt) 2013-01-16
PL206576B1 (pl) 2010-08-31
PL205041B1 (pl) 2010-03-31
IL194230A0 (en) 2011-08-01
CA2356836C (en) 2011-09-13
IL143905A (en) 2011-05-31
CN100398653C (zh) 2008-07-02
EP2261358A3 (en) 2011-02-23
EP1141306A2 (en) 2001-10-10
JP2010142246A (ja) 2010-07-01
PL349777A1 (en) 2002-09-09
WO2000039299A3 (en) 2000-11-02
DE69938670D1 (de) 2008-06-19
DK2261358T3 (da) 2014-07-28
BR9916477A (pt) 2004-06-22
CY1114722T1 (el) 2016-10-05
CA2356836A1 (en) 2000-07-06
CN1332803A (zh) 2002-01-23
OA11736A (en) 2005-06-12
NO20013045L (no) 2001-08-20
CZ20012161A3 (cs) 2001-10-17
EA007409B1 (ru) 2006-10-27
AP2001002199A0 (en) 2001-09-30
CL2009002037A1 (es) 2010-06-25
MXPA01006427A (es) 2002-06-04
JP2002533123A (ja) 2002-10-08
HUP0104774A3 (en) 2007-10-29
HUP0104774A2 (hu) 2002-04-29
KR20080036666A (ko) 2008-04-28
CY1108223T1 (el) 2014-02-12
TR200200633T2 (tr) 2002-06-21
KR20100063814A (ko) 2010-06-11
AR029322A1 (es) 2003-06-25
CN1191362C (zh) 2005-03-02
TR200102497T2 (tr) 2002-01-21
NO330800B1 (no) 2011-07-18
UY25877A1 (es) 2000-08-21
PT2261358E (pt) 2014-07-30
EP2261358B1 (en) 2014-05-14
IL194230A (en) 2013-12-31
ES2480417T3 (es) 2014-07-28
PL204073B1 (pl) 2009-12-31
PT1141306E (pt) 2008-07-30
ATE394489T1 (de) 2008-05-15
AU1764900A (en) 2000-07-31
CN101134775A (zh) 2008-03-05
KR101170203B1 (ko) 2012-07-31
KR100802198B1 (ko) 2008-02-11
ZA200105114B (en) 2002-11-21

Similar Documents

Publication Publication Date Title
KR100891398B1 (ko) 신규한 스트렙토코커스 항원
JP5051959B2 (ja) ストレプトコッカス抗原
US7262024B2 (en) Streptococcus antigens
US8211437B2 (en) Streptococcus antigens
KR100771148B1 (ko) 그룹 ｂ 스트렙토코커스 항원
US7074415B2 (en) Streptococcus antigens
EP1950302B1 (en) Streptococcus antigens
AU2008229967B2 (en) Novel streptococcus antigens
HK1118575B (en) Streptococcus antigens

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20160326

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160326

St.27 status event code: N-4-6-H10-H13-oth-PC1903